Clovis Oncology Inc (NASDAQ:CLVS) has been given an average rating of “Buy” by the twenty-one analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $89.54.
A number of research firms have recently issued reports on CLVS. Royal Bank of Canada raised shares of Clovis Oncology from a “sector perform” rating to an “outperform” rating and set a $81.00 price target on the stock in a research note on Thursday. Zacks Investment Research raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Wednesday. Evercore ISI raised shares of Clovis Oncology from an “in-line” rating to an “outperform” rating and set a $72.00 price target on the stock in a research note on Thursday. They noted that the move was a valuation call. BidaskClub downgraded shares of Clovis Oncology from a “sell” rating to a “strong sell” rating in a research note on Friday, February 9th. Finally, ValuEngine raised shares of Clovis Oncology from a “sell” rating to a “hold” rating in a research note on Friday, December 29th.
In related news, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $60.00, for a total transaction of $270,000.00. Following the sale, the director now directly owns 25,618 shares of the company’s stock, valued at approximately $1,537,080. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $59.16, for a total transaction of $177,480.00. Following the sale, the insider now directly owns 183,571 shares in the company, valued at $10,860,060.36. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 18,000 shares of company stock worth $1,094,595. 12.50% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in CLVS. PNC Financial Services Group Inc. increased its stake in Clovis Oncology by 0.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock worth $265,000 after buying an additional 20 shares during the period. California Public Employees Retirement System increased its position in shares of Clovis Oncology by 8.3% in the 2nd quarter. California Public Employees Retirement System now owns 29,900 shares of the biopharmaceutical company’s stock valued at $2,800,000 after purchasing an additional 2,300 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Clovis Oncology in the 2nd quarter valued at approximately $2,328,000. Royal Bank of Canada increased its position in shares of Clovis Oncology by 4,191.4% in the 2nd quarter. Royal Bank of Canada now owns 59,694 shares of the biopharmaceutical company’s stock valued at $5,588,000 after purchasing an additional 58,303 shares during the last quarter. Finally, Gotham Asset Management LLC purchased a new stake in shares of Clovis Oncology in the 2nd quarter valued at approximately $349,000.
Clovis Oncology (NASDAQ:CLVS) traded up $1.22 during trading on Friday, hitting $54.93. 1,187,500 shares of the stock were exchanged, compared to its average volume of 1,362,559. The stock has a market cap of $2,632.59, a P/E ratio of -7.13 and a beta of 1.05. Clovis Oncology has a twelve month low of $45.42 and a twelve month high of $99.45. The company has a quick ratio of 3.16, a current ratio of 3.19 and a debt-to-equity ratio of 0.94.
ILLEGAL ACTIVITY WARNING: This piece of content was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/22/clovis-oncology-inc-clvs-receives-89-63-consensus-target-price-from-analysts.html.
About Clovis Oncology
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.